tbuckley/cabot-search huggingface dataset:
The effectivenness of the Parent-mediated intervention for Autism Spectrum disorder in South Asia (PASS): a Randomised Controlled Trial in India and Pakistan
Authors: Green J, Emsley R, Rahman A, Patel, Hamdani S, Taylor C, Minhas A, Leadbitter K, Gauridivan, Aldred C, Cardozo P, V P Vajaratkar
Journal: The Lancet Psychiatry (2015)
Reduced-Intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Patients Older Than 60 Years.
Authors: Alessandro Busca, Franco Locatelli, Stella Santarone, Franco Narni, Enrico Morello, Alessandro Rambaldi, Nicola Mordini, Benedetto Bruno, Andrea Bacigalupo, Michele Falda
Journal: Blood (2004)
Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation
Authors: Kathryn F. Flack, Jay Desai, Jennifer M. Kolb, Prapti Chatterjee, Lars C. Wallentin, Michael Ezekowitz, Salim Yusuf, Stuart Connolly, Paul Reilly, Martina Brueckmann, John Ilgenfritz, James Aisenberg
Journal: Clinical Gastroenterology and Hepatology (2016)
Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT) in Children with Acute Leukemia: Risks and Benefits of Umbilical Cord Blood (CB) vs. Bone Marrow (BM).
Authors: Pablo Rubinstein, Mary Eapen, Cladd Stevens, Joanne Kurtzberg, Andromachi Scaradavou, John Klein, Mary Horowitz, John Wagner
Journal: Blood (2005)
Patterns of antidepressant use among women initiating tamoxifen therapy for the treatment of breast cancer in Ontario, Canada.
Authors: C. M. Kelly, T. Gomes, M. Duong-Hua, K. I. Pritchard, L. F. Paszat, D. N. Juurlink
Journal: Journal of Clinical Oncology (2010)

1592 Background: Depression occurs in up to 30% of women with breast cancer and often requires antidepressant (AD) treatment. Recent data suggests that concomitant use of certain antidepressants – paroxetine in particular - with tamoxifen may impair tamoxifen's effectiveness. We characterized antidepressant prescribing patterns in women initiating tamoxifen for breast cancer in Ontario, Canada. Methods: Using the Ontario Public Drug Benefit program, we identified women aged 66 years or older who initiated tamoxifen treatment between 1993 and 2005 and who had a record of breast cancer in the Ontario Cancer Registry. We used prescription records to determine the frequency, type, duration and timing of AD use during tamoxifen therapy. Results: We identified 24,430 who women initiated tamoxifen therapy for breast cancer during the 13 year study period. Of these, 7,483 (31%) received an AD at some time during tamoxifen therapy. The median age was 74 years, and the median duration of tamoxifen use was 3.39 years. Most women (n= 3887, 52%) were receiving an AD in the 6 months before starting tamoxifen and continued it during tamoxifen therapy. A further 285 women (4%) received an AD only in the 6 months before starting tamoxifen. The remaining 3,311 women (44%) initiated an AD after tamoxifen therapy began. A total of 3974 patients (53%) received a single AD class, while 2582 (35%) received two classes and 927 (12%) received three or more. Selective serotonin re-uptake inhibitors (SSRIs) comprised 56% of AD prescriptions dispensed. Of patients dispensed an SSRI, paroxetine was the most frequently prescribed (n = 1,938, 11.6%), followed by sertraline (n = 1,872, 11.2%); citalopram (n = 1,762, 10.6%); venlafaxine (n = 1,205 7.2%); fluoxetine (n = 994, 6.0%) and fluvoxamine (n = 772, 4.6%). The median duration of SSRI use was 18.7 months. Conclusions: In this cohort of older women with breast cancer, about 30% received an AD in combination with tamoxifen. Exposure to multiple ADs was common, particularly SSRIs, with paroxetine the most commonly prescribed in this class. This is particularly relevant in light of the potency of CYP2D6 inhibition by paroxetine, which may compromise the effectiveness of tamoxifen. No significant financial relationships to disclose.
Occurrence of <i>BRCA1–2</i> mutations and overall survival among breast cancer patients from Sardinia
Authors: G. Palmieri, G. Palomba, A. Loi, A. Uras, M. Budroni, A. Contu, A. Cossu, A. Farris, L. Crisponi, M. Monne
Journal: Journal of Clinical Oncology (2009)

e22215 Background: Germline mutations in BRCA1-2 genes have been demonstrated to increase the risk of developing breast cancer. Conversely, the impact of BRCA1–2 mutations on prognosis and survival of breast cancer patients is still debated. In this study, we extensively investigated the prevalence and geographical distribution of BRCA1–2 mutations in the entire genetically-homogeneous Sardinian population as well as tried to clarify the influence of such mutations on breast cancer-specific survival. Methods: Among incident cases during the period 1997–2002, a total of 512 breast cancer patients gave their consent to undergo BRCA1–2 mutation screening by DHPLC analysis and automated DNA sequencing. The Hakulinen, Kaplan- Meier, and Cox regression methods were used for both relative survival assessment and statistical analysis. Results: A lower breast cancer-specific overall survival rate was observed in BRCA1–2 mutation-positive patients after the first two years from diagnosis. However, survival rates were similar in both groups after five years from diagnosis. No significant difference was found for age of onset, disease stage, and primary tumour histopathology between the two subsets. The geographical distribution of BRCA1–2 mutations was related to specific three large areas of Sardinia: a) the northern area, linguistically different from the rest of the island (where a BRCA2–8765delAG mutation with founder effect was predominant); b) the central-eastern area, land of the ancient Sardinian population (where BRCA2 mutations are still largely more common thanBRCA1 mutations); and c) the south-western area, with many Phoenician and Carthaginian locations (where BRCA1 mutations are prevalent). Conclusions: In Sardinian breast cancer population, the effects of BRCA1–2 germline mutations on patients' survival were demonstrated to vary within the first two years from diagnosis. After a longer follow-up observation, breast cancer-specific rates of death were instead similar for BRCA1–2 mutation carriers and non-carriers. Finally, we identified some probands' phenotypic features which may be predictive for the presence of BRCA1–2 germline mutations and should be therefore considered when counselling patients about undergoing genetic testing. No significant financial relationships to disclose.
The Association of Dyslipidemia With Chronic Lymphocytic Leukemia: A Population-Based Study
Authors: Lee Mozessohn, Craig Earle, David Spaner, Stephanie Y. Cheng, Matthew Kumar, Rena Buckstein
Journal: JNCI Journal of the National Cancer Institute (2016)

Background: Metabolic syndrome (MetS) is a risk factor for development of cancer. Because aberrant lipid metabolism is a pathogenic feature of chronic lymphocytic leukemia (CLL), our objective was to determine if CLL patients have a higher prevalence of MetS preceding diagnosis and to determine the impact of lipid-lowering medications on survival. Methods: We conducted a population-based case-control study in Ontario, Canada, using administrative databases of adults age 66 years and older to compare the prevalence of MetS preceding CLL with age- and sex-matched control subjects. Logistic regression was used to study the association between MetS and its components to CLL. The Kaplan-Meier method and Cox Regression were used to investigate survival. All statistical tests were two-sided. Results: We identified 2124 persons with CLL and 7935 control subjects from January 1, 2000, to December 31, 2005, with follow-up until March 31, 2014, three years from the date of last contact with the health care system, or death. The mean age was 75.6 years, 20.2% had diabetes, 35.8% had hypertension, and 17.6% had dyslipidemia. In multivariable analysis, dyslipidemia (odds ratio [OR] = 1.26, 95% confidence interval [CI] = 1.11 to 1.44, P < .001) and hypertension (OR = 1.12, 95% CI = 1.01 to 1.25, P = .03) were associated with the development of CLL, whereas MetS and diabetes were not. Lipid-lowering medication was associated with a statistically significant improved survival in patients with CLL (HR = 0.53, 95% CI = 0.47 to 0.61, P < .001). Conclusions: We demonstrate a higher prevalence of dyslipidemia preceding a diagnosis of CLL compared with control subjects, supporting preclinical data. Lipid-lowering medications appear to confer a survival advantage in CLL. Prospective studies are needed to confirm these results and test their potential as therapeutic applications.
Angiopoietin-1 and Osteopontin Expression by CD138+ Myeloma Cells Rather Than VEGF and CD45 Correlates with Bone Marrow Angiogenesis in Multiple Myeloma Patients at the Diagnosis.
Authors: Nicola Giuliani, Simona Colla, Francesca Morandi, Sabrina Bonomini, Mirca Lazzaretti, Cristina Mancini, Monica Crugnola, Sara Tagliaferri, Rita Rizzato, Eugenia Martella, Gabriella Sammarelli, Luisa Craviotto, Cecilia Caramatti, Marcellina Mangoni, Vittorio Rizzoli
Journal: Blood (2005)
Correlation between the chemical composition of thermoresponsive nanogels and their interaction with the skin barrier
Authors: Michael Giulbudagian, Fiorenza Rancan, André Klossek, Kenji Yamamoto, Jana Jurisch, Victor Colombo Neto, Petra Schrade, Sebastian Bachmann, Eckart Rühl, Ulrike Blume-Peytavi, Annika Vogt, Marcelo Calderón
Journal: Journal of Controlled Release (2016)
Rectal malignancies in B. P. Koirala Memorial Cancer Hospital: A 10-year experience.
Authors: B. Acharya, A. K. Jha, S. Shretha, A. Karn, R. B. Bhandari, S. Poudel, S. Sharma, P. Neupane
Journal: Journal of Clinical Oncology (2010)

e14127 Background: Colorectal cancer is one of the most common malignancies accounting for 9%-10% of human cancers worldwide. The median age of patient suffering from this cancer is seventh decade. The incidence and mortality rates have been higher in developed countries which may be related to dietary habit and sedentary life style. In contrast to the international scenario, mainly the patients of rectal cancers attending our hospital are generally younger and of lower to middle economic group. The primary objective of this study was to find out the demographic pattern of the patients of rectal cancer and the statistical status of the disease. Methods: Total number of patients of rectal cancer, along with their age and gender, registered in a period of ten years from 1999 to 2008, were retrieved from the record section. Out of them 245 case record files were randomly selected. Demographic information, presenting complaints, disease status, radiological findings, treatments provided, follow up, and further management of each patient were recorded in a format and analyzed. Results: All together 21,025 cancer patients were registered in the period of 10 years. Out of which 2,330 (16.65%) cases were of gastrointestinal tract cancers and 388 (1.85%) cases were of rectal cancer. Out of 388 cases, 203 (52.31%) cases were male and 185 (47.69%) female. The age range was 15 to 96; the median age at the diagnosis was 46.5 years. Out of 245 patients, about 2.58% patients were diagnosed under age 20; 23.97% between 20 and 34; 18.56% between 35 and 44; 17.01% between 45 and 54; 20.10% between 55 and 64; 13.66% between 65 and 74; 3.35% between 75 and 84; 0.77% in 85 + years of age. About 93.7% of the cases were of adenocarcinoma histology. About 17.92% of patients had metastatic disease when they first came to hospital. Only 103 patients underwent surgery, and only 64 patients could complete the standard treatment. Only 59 patients came for follow-up after treatment. Only 23 patients were disease free until their last visit. Conclusions: The incidence of rectal cancer in Nepal is less in comparison to developed countries. Median age at the onset of disease is also very less which warrants a vigorous research to establish the causative factor. No significant financial relationships to disclose.
Association of GRP78 polymorphisms with response and TTP in patients with mCRC treated with FOLFOX/BV or XELOX/BV.
Authors: H. Lenz, W. Zhang, D. Yang, A. B. El-Khoueiry, Y. Ning, A. Pohl, P. O. Bohanes, K. D. Danenberg, T. Winder
Journal: Journal of Clinical Oncology (2010)

3590 Background: GRP78, a major endoplasmatic chaperone, is suggested to be critical for tumor angiogenesis. Recent data suggested GRP78 protein overexpression as a major player in tumor recurrence and poor survival by protecting cancer cells from apoptosis, promoting metastasis and chemoresistance to doxorubucin hydrochloride in breast tumors. We tested whether germ-line polymorphisms within the GRP78 gene were associated with clinical outcome in mCRC patients treated with FOLFOX/BV or XELOX/BV and investigated if there is a correlation with gene expression levels of VEGF and its receptors. Methods: gDNA was isolated from peripheral blood of 91 patients with mCRC and three potentially functional genotypes (rs391957, rs12009, rs17840761) within the GRP78 gene were determined using PCR-RFLP. mRNA was extracted from laser-capture-microdissected tumor tissue. Intratumoral gene expression levels of VEGF and VEGFR-1,-2 and -3 from 79 patients with mCRC were analyzed by RT-PCR. Results: In univariate analysis two GRP78 SNPs (rs391957 and rs12009) were significantly associated with TTP (Table). In multivariate analysis GRP78rs391957 remained significantly associated with TTP (adjusted p value=0.012). Moreover, two GRP78 polymorphisms (rs391957 and rs12009) were in linkage disequilibrium (D′=0.93 and r2=0.73). Patients harbouring the C-A-T haplotype were at lowest risk to develop tumor progression [HR 0.49 (CI 95 %; 0.29-0.82)] and showed the highest response rate [OR 2.56(CI 95%;1.07- 6.22)]. The three tested GRP78 polymorphisms were not associated with gene expression levels of VEGF or its receptors (p values > 0.05). Conclusions: Our data suggest that polymorphisms in GRP78 gene may be potential predictive markers to FOLFOX/BV or XELOX/BV therapy in mCRC patients. Moreover, GRP78 polymorphisms may play a major role in VEGF-independent tumor angiogenesis. Univariate analysis N Time to progression Median, months (95% CI) P* value GRP78rs391957 0.004 CC 33 7.9 (6.9, 12.4) CT 35 15.8 (10.8, 22.9) TT 5 19.9 (1.9, 38.6) GRP78rs12009 0.021 TT 31 8.1 (7.0, 11.7) TC 36 13.9 (10.8, 22.2) CC 7 19.9 (7.8, 38.6) GRP78rs17840761 0.074 AA 22 8.3 (6.9, 15.0) AG 41 12.4 (8.1, 17.0) GG 13 13.9 (12.4, 38.6) * Log-rank test. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Response Genetics Genentech Response Genetics
GW26-e5358 Apelin/APJ Signaling Promotes Hypoxia-Induced Proliferation of Endothelial Progenitor Cells Via PI3K/Akt Signaling
Authors: Jingchang Zhang, Qiming Liu, Xinqun Hu, Zhenfei Fang, Liang Tang, Shenghua Zhou
Journal: Journal of the American College of Cardiology (2015)
Utility of Oligonucleotide Array Comparative Genomic Hybridization to Identify Cryptic Copy Number Alterations in Myelodysplastic Syndromes
Authors: Wendy K Chung, James Weisberger, Yi Sun, Pauline Brenholz, Stephanie Warren, Brigette A Brown-Kipphut, Swaroop Aradhya, Charles A LeDuc, Marc Grodman, Richard Burack, M. Anwar Iqbal, John M. Bennett
Journal: Blood (2008)
Inhibition of SRF/myocardin reduces aortic stiffness by targeting vascular smooth muscle cell stiffening in hypertension
Authors: Ning Zhou, Jia-Jye Lee, Shaunrick Stoll, Ben Ma, Robert Wiener, Charles Wang, Kevin D. Costa, Hongyu Qiu
Journal: Cardiovascular Research (2016)

Increased aortic stiffness is a fundamental manifestation of hypertension. However, the molecular mechanisms involved remain largely unknown. We tested the hypothesis that abnormal intrinsic vascular smooth muscle cell (VSMC) mechanical properties in large arteries, but not in distal arteries, contribute to the pathogenesis of aortic stiffening in hypertension, mediated by the serum response factor (SRF)/myocardin signalling pathway.Four month old male spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto (WKY) rats were studied. Using atomic force microscopy, significant VSMC stiffening was observed in the large conducting aorta compared with the distal arteries in SHR (P < 0.001), however, this regional variation was not observed in WKY rats (P > 0.4). The increase of VSMC stiffness was accompanied by a parallel increase in the expression of SRF by 9.8-fold and of myocardin by 10.5-fold in thoracic aortic VSMCs from SHR vs. WKY rats, resulting in a significant increase of downstream stiffness-associated genes (all, P < 0.01 vs. WKY). Inhibition of SRF/myocardin expression selectively attenuated aortic VSMC stiffening, and normalized downstream targets in VSMCs isolated from SHR but not from WKY rats. In vivo, 2 weeks of treatment with SRF/myocardin inhibitor delivered by subcutaneous osmotic minipump significantly reduced aortic stiffness and then blood pressure in SHR but not in WKY rats, although concomitant changes in aortic wall remodelling were not detected during this time frame.SRF/myocardin pathway acts as a pivotal mediator of aortic VSMC mechanical properties and plays a central role in the pathological aortic stiffening in hypertension. Attenuation of aortic VSMC stiffening by pharmacological inhibition of SRF/myocardin signalling presents a novel therapeutic strategy for the treatment of hypertension by targeting the cellular contributors to aortic stiffness.
YM150, an Oral Direct Factor Xa Inhibitor, as Prophylaxis for Venous Thromboembolism in Patients with Elective Primary Hip Replacement Surgery. A Dose Escalation Study.
Authors: Bengt I. Eriksson, Alexander G.G. Turpie, Michael R. Lassen, Martin H. Prins, Giancarlo Agnelli, Marleen L. Gaillard, Bert Meems
Journal: Blood (2005)
A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC).
Authors: Christine Marie Lovly, Chung-I Li, Anne Smith Hutchison, David Paul Carbone, David H. Johnson, Vicki Leigh Keedy, William Pao, Alan Sandler, Leora Horn
Journal: Journal of Clinical Oncology (2012)

7094 Background: Bendamustine is an alkylating agent with a nitrogen mustard group and purine-like benzimidazole group. Bendamustine in combination with carboplatin has shown efficacy as first line therapy in extensive stage SCLC with RR 73%, TTP 5.2 months and OS 8.3 months [Köster, et al, JCO 2007]. This study aims to investigate the efficacy and safety of single agent bendamustine as 2nd or 3rd line therapy in patients with extensive-stage disease, small-cell lung cancer (ED-SCLC). Methods: This is an open-label, single-arm, multicenter phase II trial. Eligible patients had previously treated ED-SCLC, up to 2 prior regimens, ECOG performance status 0-2, evaluable/measurable disease, and adequate marrow, renal and hepatic function. Patients with stable treated brain metastases were allowed. Patients were treated with bendamustine (120mg/m 2 IV days 1 and 2 every 3 weeks) for up to 6 cycles. Evaluation occurred every 2 cycles. Primary endpoint was TTP; secondary endpoints include RR, PFS, OS, and toxicity. Results: 48 patients were enrolled; 56% were male and 96% were Caucasian. 33 patients were evaluable for response. There was 1 CR, 9 PR, 13 SD (48% disease control rate) and 10 PD. Median TTP was 3.37 months (95% CI 2.30 to 4.47 months). At the time of analysis, 13 patients were alive and with a median overall survival of 4.77 months (95% CI 3.67 to 6.07 months). 5 patients (10.4%) required dose reductions due to AEs, 2 due to fatigue, 1 due to neutropenia, 1 due to pancytopenia and 1 due to pneumonia. Grade 3/4 AEs included fatigue (18.8%), dyspnea (14.5%), infection without neutropenia (12.5%), anemia (8.3%), neutropenia (8.3%), and diarrhea (8.3%). Conclusions: These data indicate that single agent bendamustine appears to be well tolerated and effective in the second or third line setting for patients with SCLC.
Genome-Wide Analysis of Alternative Splicing Points to Novel Leukemia Relevant Genes in Acute Myeloid Leukemia.
Authors: Anna Dolnik, Andreas Gerhardinger, Ursula Botzenhardt, Sabrina Heinrich, Richard Schlenk, Hartmut Dohner, Konstanze Doehner, Karlheinz Holzmann, Lars Bullinger
Journal: Blood (2009)
GW26-e2303 Suboptimal oral anticoagulation use among Chinese nonvalvular Atrial Fibrillation Patients: the Nanchang Atrial Fibrillation project
Authors: Qinmei Xiong, Alena Shantsila, Xiaoshu Cheng, Kui Hong, Gregory YH Lip
Journal: Journal of the American College of Cardiology (2015)
FcγRIIa Enhances Thrombus Growth in Vitro and in Vivo
Authors: Huiying Zhi, Lubica Rauova, Vincent M Hayes, Jimmy Crockett, Cunji Gao, Brian Boylan, Debra K. Newman, Steven McKenzie, Brian C. Cooley, Mortimer Poncz, Peter J. Newman
Journal: Blood (2011)
Epigenetic Memory Enables the Dominant Generation of Adult-Type Erythrocytes From Human Induced Pluripotent Stem Cells
Authors: Naoya Takayama, Shiya Sano, Takafumi Shimizu, Ryoichiro Kawahata, Hiroshi Endo, Sou Nakamura, Seishi Ogawa, Hiromitsu Nakauchi, Koji Eto
Journal: Blood (2010)
Impact of Minimal Residual Disease (MRD) on Prognosis in Children with Philadelphia Positive Acute Lymphoblastic Leukemia (ALL) Treated in the AIEOP-BFM ALL 2000 Study.
Authors: Andrea Biondi, André Schrauder, Maria Grazia Valsecchi, Claus R Bartram, Georg Mann, Giulio De Rossi, Anja Möricke, Rosanna Parasole, Jochen Harbott, Chiara Messina, C. Rizzari, Giuseppe Masera, Martin Schrappe
Journal: Blood (2008)
A phase I study of induction chemotherapy (CT) and concomitant chemoradiotherapy (CRT) with carboplatin (C), paclitaxel (P), and irinotecan (I) for stage III non-small cell lung cancer (NSCLC)
Authors: P. K. Tothy, A. M. Mauer, D. Haraf, C. M. Rudin, P. C. Hoffman, M. K. Ferguson, L. Szeto, E. E. Vokes
Journal: Journal of Clinical Oncology (2004)

7170 Background: A standard therapy for unresectable stage III NSCLC includes CT with P & C followed by concomitant P & C with radiotherapy (RT) (CALGB 39801). Preclinical data indicates synergy between I & C and I & P. Their combined administration might result in a further increase of antitumor activity. Preclinical data also suggests RT enhancement by each of the 3 drugs. This phase I study evaluated a regimen of CT with IPC followed by CRT with IPC in patients (pts) with stage III NSCLC. Methods: The CT regimen (JCO 19:2001, 1078) consisted of two 21-day cycles of I (100mg/m2 on d1), P (175 mg/m2 on d1) & C (AUC=5 on d1). During XRT (50 Gy for resectable and 66 Gy for unresectable) pts received weekly chemotherapy of I, P, & C in sequential cohorts of dose levels (Table 1). Accrual to dose level IV has been completed. Eligibility criteria included CALGB performance status (PS) ≤2 and stage III NSCLC without prior CT or RT. Results: 38 pts were enrolled with median age 63; PS 0/1/2 in 15/19/4. Toxicity during CT included grade 3/4 neutropenia (17); grade 3 hemoglobin (1); grade 3 diarrhea (1); neutropenic fever (2); neutropenic infection (1). 3 pts had distant progression & 3 pts had local progression during CT. 26 pts have been evaluated for CRT. Dose-limiting toxicities (DLTs) for CRT were grade 3 neutropenia > 1 wk: dose I (3/75%), II (3/50%), III (2/18%). Other toxiticites: grade 3 esophagitis in 12/26 pts & grade 3 radiation pneumonitis in 1 pt in dose II. The regimen demonstrated significant activity with 14 pts having partial response after CT + CRT. 6 pts had surgical resection after CRT & 2 pts had a complete response. Conclusions: DLT is neutropenia of duration > 1 wk. Dose level IV is currently under evaluation and is likely the maximally tolerated dose of I & P that can be administered with CRT. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Pfizer
The BH3-Only Protein Puma Plays An Essential Role in p53-Mediated Apoptosis of Chronic Lymphocytic Leukemia Cells
Authors: Wei Xu, Hai-Jia Zhu, Li-Na Zhang, Lei Fan, Cheng Fang, Dan-Xia Zhu, Yin-Hua Wang, Jian-Yong Li
Journal: Blood (2011)